Skip to content

Efficacy evaluation of online lymphoedema prevention support program

Efficacy evaluation of online lymphoedema prevention support program after breast and gynaecologic cancer surgery: a single-arm trial - Efficacy evaluation of online lymphoedema prevention support program after breast and gynaecologic cancer surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050309
Enrollment
90
Registered
2023-02-12
Start date
2023-10-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, gynaecologic cancer (cervical cancer, endometrial cancer, ovarian cancer/fallopian tube cancer/peritoneal cancer)

Interventions

We provide a four-session online lymphoedema prevention support program (60 minutes per session). The 1st to 3rd sessions are held every month, and the 4th session is held 6 months after the 3rd sessi

Sponsors

Musashino University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients who underwent surgery for breast cancer, gynaecologic cancer (cervical cancer, endometrial cancer, or ovarian cancer/fallopian tube cancer/peritoneal cancer) (regardless of multiple cancers, stage, or years since surgery); 2. Women, 18 years old or older at the time of consent; 3. Those who are physically and mentally able to participate in this research; 4. Those who have proficiency in Japanese; 5. Those who have personal computers or mobile devices such as tablets and mobile phones; 6. Those who have access to the internet; 7. Those who can access online meeting platforms; 8. Those who plan to participate in all four-sessions of the online lymphoedema prevention support program; 9. Those who can give either electronic or written consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are undergoing treatment or follow-up, and judged by their doctors to be unsuitable for this study at the time of either electronic or written consent; 2. Those who are already diagnosed with lymphoedema at the time of registration for this study.

Design outcomes

Primary

MeasureTime frame
The assessment time points of the primary outcome are before program attendance (T0), after completion of the 3rd session (T1:3 months after T0), and after completion of the 4th session (T2: 9 months after T0). The primary outcome is self-efficacy in self-care of lymphoedema prevention.

Secondary

MeasureTime frame
1. Knowledge of self-care for lymphoedema prevention (T0, T1, T2) 2. Anxiety and stress with lymphoedema and self-care (T0, T1, T2) 3. BMI (every month between the 1st and the 4th sessions) 4. QOL (T0, T1, T2) 5. Fatigue (T0) 6. Degree of understanding, enjoyment, and satisfaction with each session (after the 1st, 2nd, 3rd, and 4th sessions) 7. Self-monitoring of self-care (monthly between the 1st and 4th sessions)

Countries

Japan

Contacts

Public ContactMiyako Tsuchiya

Musashino University Research Institute of Nursing

k033551@ptf.musashino-u.ac.jp0355307730

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026